246 related articles for article (PubMed ID: 37899132)
21. Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.
Kang CY; Duarte SE; Kim HS; Kim E; Park J; Lee AD; Kim Y; Kim L; Cho S; Oh Y; Gim G; Park I; Lee D; Abazeed M; Velichko YS; Chae YK
Oncologist; 2022 Jun; 27(6):e471-e483. PubMed ID: 35348765
[TBL] [Abstract][Full Text] [Related]
22. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
23. Top 10 Challenges in Cancer Immunotherapy.
Hegde PS; Chen DS
Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268
[TBL] [Abstract][Full Text] [Related]
24. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
25. Biotech and Breakthroughs in Immuno-Oncology.
Bockman JM
Urol Clin North Am; 2020 Nov; 47(4):511-521. PubMed ID: 33008500
[TBL] [Abstract][Full Text] [Related]
26. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
27. Immuno-oncology trends: preclinical models, biomarkers, and clinical development.
Franklin MR; Platero S; Saini KS; Curigliano G; Anderson S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022192
[TBL] [Abstract][Full Text] [Related]
28. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
Hernando-Calvo A; Vila-Casadesús M; Bareche Y; Gonzalez-Medina A; Abbas-Aghababazadeh F; Lo Giacco D; Martin A; Saavedra O; Brana I; Vieito M; Fasani R; Stagg J; Mancuso F; Haibe-Kains B; Han M; Berche R; Pugh TJ; Mirallas O; Jimenez J; Gonzalez NS; Valverde C; Muñoz-Couselo E; Suarez C; Diez M; Élez E; Capdevila J; Oaknin A; Saura C; Macarulla T; Galceran JC; Felip E; Dienstmann R; Bedard PL; Nuciforo P; Seoane J; Tabernero J; Garralda E; Vivancos A
Med; 2023 Oct; 4(10):710-727.e5. PubMed ID: 37572657
[TBL] [Abstract][Full Text] [Related]
29. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
30. Neuro-immune interactions and immuno-oncology.
Khanmammadova N; Islam S; Sharma P; Amit M
Trends Cancer; 2023 Aug; 9(8):636-649. PubMed ID: 37258398
[TBL] [Abstract][Full Text] [Related]
31. Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time.
Almagro J; Messal HA
Front Immunol; 2023; 14():1176594. PubMed ID: 37261345
[TBL] [Abstract][Full Text] [Related]
32. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
33. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Perspective of Immunotherapy for Cancers.
Keshari S; Barrodia P; Singh AK
Cells; 2023 Jan; 12(3):. PubMed ID: 36766706
[TBL] [Abstract][Full Text] [Related]
35. In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.
DiMarco AV; Maddalo D
Curr Protoc; 2022 Mar; 2(3):e377. PubMed ID: 35255200
[TBL] [Abstract][Full Text] [Related]
36. Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.
Han ZJ; Li YB; Yang LX; Cheng HJ; Liu X; Chen H
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011369
[TBL] [Abstract][Full Text] [Related]
37. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.
Parra ER; Zhai J; Tamegnon A; Zhou N; Pandurengan RK; Barreto C; Jiang M; Rice DC; Creasy C; Vaporciyan AA; Hofstetter WL; Tsao AS; Wistuba II; Sepesi B; Haymaker C
Sci Rep; 2021 Feb; 11(1):4530. PubMed ID: 33633208
[TBL] [Abstract][Full Text] [Related]
38. Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Mazzarella L; Morganti S; Marra A; Trapani D; Tini G; Pelicci P; Curigliano G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238471
[TBL] [Abstract][Full Text] [Related]
39. The future of cancer immunotherapy: DNA vaccines leading the way.
Pandya A; Shah Y; Kothari N; Postwala H; Shah A; Parekh P; Chorawala MR
Med Oncol; 2023 Jun; 40(7):200. PubMed ID: 37294501
[TBL] [Abstract][Full Text] [Related]
40. Imaging Mass Cytometry in Immuno-Oncology.
Cotechini T; Jones O; Hindmarch CCT
Methods Mol Biol; 2023; 2614():1-15. PubMed ID: 36587115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
